© 2026 Buobe

ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial | Buobe

ArkBio's RSV Antiviral Drug Ziresovir Receives FDA Approval for Phase II Clinical Trial

Published by

on •1 min read

SHANGHAI, Aug. 14, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd.

ArkBio Ziresovir AK0529 FDA approval Phase II clinical trial Receives Approved